Literature DB >> 27634430

Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a.

Rezwanul Wahid1, Stephanie Fresnay1, Myron M Levine2, Marcelo B Sztein3.   

Abstract

The live oral typhoid vaccine Ty21a elicits predominantly CD8+, as well as CD4+ T cells mediated immune responses. Clinical field studies showed that Ty21a is moderately effective against S. Typhi and S. Paratyphi B, but not S. Paratyphi A infections. In this study we describe the in depth characterization of S. Typhi, S. Paratyphi A and S. Paratyphi B cross-reactive CD4+ T cell responses elicited following immunization with Ty21a. PBMC samples were collected from 16 healthy volunteers before and 42/84days after Ty21a immunization and stimulated ex-vivo with Salmonella-infected targets. Multiparametric flow cytometry was used to detect the vaccine elicited Salmonella-specific responses in T effector/memory (TEM) and CD45RA+ T effector/memory (TEMRA) CD4+ cell subsets, by measuring CD4+ multifunctional (MF) cells that concomitantly produced IFN-γ, TNF-α, IL-2, MIP-1β, IL-17A and/or expressed CD107a. Post-vaccination increases in S. Typhi-specific MF cells were observed in CD4+ TEM and TEMRA subsets which predominantly produced IFN-γ and/or TNF-α, while IL-2 was produced by a smaller cell subset. A small proportion of those MF cells also produced MIP-1β, IL-17A and expressed CD107a (a marker associated with cytotoxicity). Approximately one third of these specific MF cells have the potential to migrate to the gut mucosa, as evidenced by co-expression of the gut-homing molecule integrin α4β7. In contrast to our previous observations with CD8+ T cells, MF CD4+ T cell responses to the different Salmonella serovars evaluated were similar in magnitude and characteristics. We conclude that although induction of cross-reactive CD4+ MF effector T cells suggest a possible role in Salmonella-immunity, these responses are unlikely to provide an immunological basis for the observed efficacy of Ty21a against S. Typhi and S. Paratyphi B, but not to S. Paratyphi A. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4 T cells; Cross-reactive; Human; Multifunctional; Salmonella; Ty21a

Mesh:

Substances:

Year:  2016        PMID: 27634430      PMCID: PMC5322816          DOI: 10.1016/j.clim.2016.09.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  54 in total

1.  Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine.

Authors:  M M Levine; C Ferreccio; P Abrego; O S Martin; E Ortiz; S Cryz
Journal:  Vaccine       Date:  1999-10-01       Impact factor: 3.641

Review 2.  Emergence of Salmonella paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines.

Authors:  Monthida Fangtham; Henry Wilde
Journal:  J Travel Med       Date:  2008 Sep-Oct       Impact factor: 8.490

3.  Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Authors:  B D Kirkpatrick; Robin McKenzie; J Patrick O'Neill; Catherine J Larsson; A Louis Bourgeois; Janet Shimko; Matthew Bentley; Jill Makin; Steve Chatfield; Zoë Hindle; Christine Fidler; Brad E Robinson; Cassandra H Ventrone; Nivedita Bansal; Colleen M Carpenter; Deborah Kutzko; Sandra Hamlet; Casey LaPointe; David N Taylor
Journal:  Vaccine       Date:  2005-08-18       Impact factor: 3.641

4.  Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine.

Authors:  C H Simanjuntak; F P Paleologo; N H Punjabi; R Darmowigoto; H Totosudirjo; P Haryanto; E Suprijanto; N D Witham; S L Hoffman
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

5.  Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses.

Authors:  M F Pasetti; R J Anderson; F R Noriega; M M Levine; M B Sztein
Journal:  Clin Immunol       Date:  1999-07       Impact factor: 3.969

6.  Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans.

Authors:  Rezwanul Wahid; Raphael Simon; Shah J Zafar; Myron M Levine; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

7.  Oral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease.

Authors:  Franklin R Toapanta; Paula J Bernal; Stephanie Fresnay; Thomas C Darton; Claire Jones; Claire S Waddington; Christoph J Blohmke; Gordon Dougan; Brian Angus; Myron M Levine; Andrew J Pollard; Marcelo B Sztein
Journal:  PLoS Negl Trop Dis       Date:  2015-06-11

Review 8.  Paratyphoid fever: splicing the global analyses.

Authors:  Cindy Shuan Ju Teh; Kek Heng Chua; Kwai Lin Thong
Journal:  Int J Med Sci       Date:  2014-05-14       Impact factor: 3.738

9.  Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans.

Authors:  R Wahid; S Fresnay; M M Levine; M B Sztein
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

10.  An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution.

Authors:  Claire S Waddington; Thomas C Darton; Claire Jones; Kathryn Haworth; Anna Peters; Tessa John; Ben A V Thompson; Simon A Kerridge; Robert A Kingsley; Liqing Zhou; Kathryn E Holt; Ly-Mee Yu; Stephen Lockhart; Jeremy J Farrar; Marcelo B Sztein; Gordon Dougan; Brian Angus; Myron M Levine; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2014-02-10       Impact factor: 9.079

View more
  17 in total

Review 1.  Antimicrobial resistance: new insights and therapeutic implications.

Authors:  Bashir Ahmad Sheikh; Basharat Ahmad Bhat; Manzoor Ahmad Mir
Journal:  Appl Microbiol Biotechnol       Date:  2022-09-19       Impact factor: 5.560

2.  A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.

Authors:  David I Bernstein; Marcela F Pasetti; Rebecca Brady; Amanda D Buskirk; Rezwanul Wahid; Michelle Dickey; Mitchell Cohen; Holly Baughman; Jill El-Khorazaty; Nicole Maier; Marcelo B Sztein; Shahida Baqar; A Louis Bourgeois
Journal:  Vaccine       Date:  2018-12-15       Impact factor: 3.641

3.  Diversity of Salmonella Typhi-responsive CD4 and CD8 T cells before and after Ty21a typhoid vaccination in children and adults.

Authors:  Mark E Rudolph; Monica A McArthur; Laurence S Magder; Robin S Barnes; Wilbur H Chen; Marcelo B Sztein
Journal:  Int Immunol       Date:  2019-04-26       Impact factor: 5.071

4.  Evolution of Salmonella Typhi outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: A randomized clinical trial.

Authors:  Juan Manuel Carreño; Christian Perez-Shibayama; Cristina Gil-Cruz; Constantino Lopez-Macias; Pietro Vernazza; Burkhard Ludewig; Werner C Albrich
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

5.  Crosstalk between leukocytes triggers differential immune responses against Salmonella enterica serovars Typhi and Paratyphi.

Authors:  Rosangela Salerno-Goncalves; Darpan Kayastha; Alessio Fasano; Myron M Levine; Marcelo B Sztein
Journal:  PLoS Negl Trop Dis       Date:  2019-08-14

6.  Attenuated Oral Typhoid Vaccine Ty21a Elicits Lamina Propria and Intra-Epithelial Lymphocyte Tissue-Resident Effector Memory CD8 T Responses in the Human Terminal Ileum.

Authors:  Jayaum S Booth; Seema A Patil; Eric Goldberg; Robin S Barnes; Bruce D Greenwald; Marcelo B Sztein
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

7.  Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans.

Authors:  Jayaum S Booth; Seema A Patil; Leyla Ghazi; Robin Barnes; Claire M Fraser; Alessio Fasano; Bruce D Greenwald; Marcelo B Sztein
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-08-16

Review 8.  Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®).

Authors:  D Amicizia; L Arata; F Zangrillo; D Panatto; R Gasparini
Journal:  J Prev Med Hyg       Date:  2017-03

9.  Longevity of duodenal and peripheral T-cell and humoral responses to live-attenuated Salmonella Typhi strain Ty21a.

Authors:  Shaun H Pennington; Daniela M Ferreira; Jesús Reiné; Tonney S Nyirenda; Ameeka L Thompson; Carole A Hancock; Angela D Wright; Stephen B Gordon; Melita A Gordon
Journal:  Vaccine       Date:  2018-06-27       Impact factor: 3.641

10.  Effect of the live oral attenuated typhoid vaccine, Ty21a, on systemic and terminal ileum mucosal CD4+ T memory responses in humans.

Authors:  Jayaum S Booth; Eric Goldberg; Seema A Patil; Robin S Barnes; Bruce D Greenwald; Marcelo B Sztein
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.